- Home
- TVRD vs IMMR Comparison
TVRD vs IMMR Comparison
Compare TVRD & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- IMMR
- Stock Information
- Founded
- TVRD 2017
- IMMR 1993
- Country
- TVRD United States
- IMMR United States
- Employees
- TVRD N/A
- IMMR N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- IMMR Computer peripheral equipment
- Sector
- TVRD Health Care
- IMMR Technology
- Exchange
- TVRD Nasdaq
- IMMR Nasdaq
- Market Cap
- TVRD 246.5M
- IMMR 251.7M
- IPO Year
- TVRD N/A
- IMMR 1999
- Fundamental
- Price
- TVRD $40.68
- IMMR $7.10
- Analyst Decision
- TVRD Strong Buy
- IMMR Strong Buy
- Analyst Count
- TVRD 5
- IMMR 2
- Target Price
- TVRD $59.20
- IMMR $12.25
- AVG Volume (30 Days)
- TVRD 67.6K
- IMMR 471.8K
- Earning Date
- TVRD 11-21-2025
- IMMR 09-11-2025
- Dividend Yield
- TVRD N/A
- IMMR 2.53%
- EPS Growth
- TVRD N/A
- IMMR 57.07
- EPS
- TVRD N/A
- IMMR 2.04
- Revenue
- TVRD N/A
- IMMR $163,133,000.00
- Revenue This Year
- TVRD N/A
- IMMR $988.71
- Revenue Next Year
- TVRD N/A
- IMMR $109.72
- P/E Ratio
- TVRD N/A
- IMMR $3.52
- Revenue Growth
- TVRD N/A
- IMMR 338.21
- 52 Week Low
- TVRD $8.13
- IMMR $6.47
- 52 Week High
- TVRD $42.10
- IMMR $10.72
- Technical
- Relative Strength Index (RSI)
- TVRD 70.68
- IMMR 47.86
- Support Level
- TVRD $36.05
- IMMR $6.96
- Resistance Level
- TVRD $42.10
- IMMR $7.48
- Average True Range (ATR)
- TVRD 2.87
- IMMR 0.20
- MACD
- TVRD 0.07
- IMMR -0.01
- Stochastic Oscillator
- TVRD 82.26
- IMMR 26.95
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.